ð¬ æ°åã³ãããŠã€ã«ã¹ãšã®æ°ããªæŠãæ¹ïŒå ç«çްèã峿¹ã«ã€ãã
æ°åã³ãããŠã€ã«ã¹ææçïŒCOVID-19ïŒã¯ãç§ãã¡ã®ç掻ã«å€§ããªåœ±é¿ãäžãç¶ããŠããŸããã¯ã¯ãã³æ¥çš®ãé²ã¿ãæ²»çè¬ãéçºãããŠããŸãããããŠã€ã«ã¹ã®å€ç°ããæ¢åã®æ²»çæ³ã§ã¯ååãªå¹æãåŸãããªãã±ãŒã¹ãååšãããããæ°ããªå¯Ÿçæè¡ã®éçºãåžžã«æ±ããããŠããŸãã
ç§ãã¡ã®äœã«ã¯ããŠã€ã«ã¹ãªã©ã®ç åäœãšæŠãããã®åŒ·åãªãå ç«ã·ã¹ãã ããåãã£ãŠããŸãããã®å ç«ã·ã¹ãã ãæå€§éã«æŽ»çšããæ°åã³ãããŠã€ã«ã¹ãå¹ççã«æé€ããæ°ããæ¹æ³ã¯ãªãããäžçäžã§ç ç©¶ãé²ããããŠããŸããä»åã玹ä»ããç ç©¶ã¯ããŸãã«ãã®å ç«ã·ã¹ãã ãç¹ã«ãèªç¶å ç«çްèãã®åãåããŠãæ°åã³ãããŠã€ã«ã¹ãæéããç»æçãªã¿ã³ãã¯è³ªã®äœè£œã«æåãããšãããã®ã§ãã
ç ç©¶ã®èæ¯ãšç®ç
æ°åã³ãããŠã€ã«ã¹ïŒSARS-CoV-2ïŒã¯ãç§ãã¡ã®çްè衚é¢ã«ãããACE2ïŒãšãŒã¹ããŒïŒããšããå容äœâ»1ã«çµåããŠçްèå ã«äŸµå ¥ããŸãããã®äŸµå ¥ãé²ãããã«ããŠã€ã«ã¹ã®çµåãéªéãããäžåæäœãããACE2ã®ãããšãïŒãã³ã€ïŒããšãªã人工ã¿ã³ãã¯è³ªãhrsACE2ïŒãšã€ãã¢ãŒã«ãšã¹ãšãŒã¹ããŒïŒãâ»2ãªã©ãéçºãããŠããŸããã
ããããäžåæäœã¯ãŠã€ã«ã¹ã®å€ç°ã«ãã£ãŠå¹æãäœäžããããšããããhrsACE2ããŠã€ã«ã¹ãžã®çµååïŒèŠªåæ§ïŒããå ç«çްèã«ããåã蟌ã¿å¹çã«èª²é¡ããããŸãããããã§æ¬ç ç©¶ã§ã¯ãhrsACE2ã«ããã³ããŒã¹ãâ»3ãšããç³éãä»å ãããMann-hrsACE2ïŒãã³-ãšã€ãã¢ãŒã«ãšã¹ãšãŒã¹ããŒïŒããšããæ°ããã¿ã³ãã¯è³ªãäœè£œããŸããããã®Mann-hrsACE2ããèªç¶å ç«ã®äž»åœ¹ã§ããããã¯ããã¡ãŒãžãâ»4ãªã©ã®å ç«çްèã«å¹çããåã蟌ãŸããããšã§ããŠã€ã«ã¹ã®äŸµå ¥ããããã¯ããã ãã§ãªããå ç«çްèã«ãããŠã€ã«ã¹æé€ã匷åã«ä¿é²ããããšãç®æããŸããã
â»1 ACE2ïŒã¢ã³ãžãªãã³ã·ã³å€æé
µçŽ 2ïŒïŒæ°åã³ãããŠã€ã«ã¹ãããã®çްèã«ææããéã«ãè¶³ããããšããŠå©çšãã现è衚é¢ã®ã¿ã³ãã¯è³ªã
â»2 hrsACE2ïŒhuman recombinant soluble ACE2ïŒïŒããã®ACE2å容äœã®äžéšã人工çã«äœãåºããã¿ã³ãã¯è³ªã现èã«çµåããªãã坿º¶æ§ãã®åœ¢ã§ååšãããŠã€ã«ã¹ã®çµåéšäœã奪ãããšã§ããŠã€ã«ã¹ã现èã«äŸµå
¥ããã®ãé²ããããšãããšããŠæ©èœããã
â»3 ãã³ããŒã¹ïŒç¹å®ã®å
ç«çްèïŒãã¯ããã¡ãŒãžãæš¹ç¶çްèãªã©ïŒã®è¡šé¢ã«ããå容äœãèªèããããç¹åŸŽãæã€ç³ã®äžçš®ã
â»4 ãã¯ããã¡ãŒãžïŒäœå
ã«äŸµå
¥ããç°ç©ããæ»ãã 现èãªã©ãæé£ã»æ¶åããã倧é£çްèããšåŒã°ããå
ç«çްèãç
åäœã®æé€ã ãã§ãªããä»ã®å
ç«çްèã«ç
åäœã®æ
å ±ãæç€ºãããæåæç€ºçްèãâ»5ãšããŠãéèŠãªåœ¹å²ãæããã
â»5 æåæç€ºçްèïŒç
åäœãåã蟌ãã åŸããã®äžéšïŒæåïŒãä»ã®å
ç«çްèïŒT现èãªã©ïŒã«æç€ºããããšã§ãããç¹ç°çã§åŒ·åãªå
ç«å¿çïŒçŽ°èæ§å
ç«ãªã©ïŒã掻æ§åããã现èã
𧪠ã©ã®ããã«ããŠæ°ããã¿ã³ãã¯è³ªãäœã£ãã®ãïŒç ç©¶æ¹æ³ã®æŠèŠ
ãã®ç»æçãªMann-hrsACE2ã¯ãã©ã®ããã«ããŠäœããããã®æ©èœã確èªãããã®ã§ãããããç ç©¶ããŒã ã¯ã以äžã®æ¹æ³ã§å®éšãé²ããŸããã
Mann-hrsACE2 (ãã³-ãšã€ãã¢ãŒã«ãšã¹ãšãŒã¹ããŒ) ã®äœè£œ
ãŸããç®çã®Mann-hrsACE2ã¿ã³ãã¯è³ªã倧éã«äœãããã«ããããã¥ããŠã€ã«ã¹çºçŸç³»ãâ»6ãšããæè¡ãçšããŠãæè«çްèïŒSf9现èïŒâ»7ã§çç£ããŸããããã®æ¹æ³ã«ãããã¿ã³ãã¯è³ªã«ãã³ããŒã¹ãªã©ã®ç³éãå¹çããä»å ããããšãã§ããŸãã
äœè£œãããã¿ã³ãã¯è³ªã¯ããNi-NTAã¯ãããã°ã©ãã£ãŒãâ»8ãšããææ³ã§äžçŽç©ãåãé€ããçŽç²ãªMann-hrsACE2ã粟補ããŸããã粟補ãããã¿ã³ãã¯è³ªã¯ããSDS-PAGEãâ»9ãããŠã§ã¹ã¿ã³ãããããâ»10ãšãã£ãåææ¹æ³ã§ããã®çŽåºŠãååéãç®çã®ã¿ã³ãã¯è³ªã§ããããšãªã©ã確èªããŸããã
â»6 ããã¥ããŠã€ã«ã¹çºçŸç³»ïŒæè«ã«ææãããŠã€ã«ã¹ïŒããã¥ããŠã€ã«ã¹ïŒã®éºäŒåãæäœããç®çã®ã¿ã³ãã¯è³ªã®éºäŒåãçµã¿èŸŒãããšã§ãæè«çްèã«ãã®ã¿ã³ãã¯è³ªã倧éã«äœãããæè¡ã
â»7 Sf9现èïŒãšããŠã¬ãšããæè«ç±æ¥ã®çŽ°èæ ªã§ãããã¥ããŠã€ã«ã¹çºçŸç³»ãçšããã¿ã³ãã¯è³ªçç£ã«ããå©çšãããã
â»8 Ni-NTAã¯ãããã°ã©ãã£ãŒïŒã¿ã³ãã¯è³ªã«ç¹å®ã®ã¿ã°ïŒç®å°ïŒãä»ããŠããããã®ã¿ã°ãããã±ã«ïŒNiïŒã«çµåããæ§è³ªãå©çšããŠãç®çã®ã¿ã³ãã¯è³ªã ããå¹ççã«åé¢ã»ç²Ÿè£œããæè¡ã
â»9 SDS-PAGEïŒããã·ã«ç¡«é
žãããªãŠã -ããªã¢ã¯ãªã«ã¢ããã²ã«é»æ°æ³³åïŒïŒã¿ã³ãã¯è³ªããã®ååéïŒãµã€ãºïŒã«å¿ããŠåé¢ããçŽåºŠãååéã確èªããåæææ³ã
â»10 ãŠã§ã¹ã¿ã³ããããïŒSDS-PAGEã§åé¢ããã¿ã³ãã¯è³ªãèã«è»¢åããç¹å®ã®æäœã䜿ã£ãŠç®çã®ã¿ã³ãã¯è³ªãæ€åºã»ç¢ºèªããåæææ³ã
ãã¯ããã¡ãŒãžãšã®çžäºäœçšã®è©äŸ¡
次ã«ãäœè£œããMann-hrsACE2ããå®éã«ãã¯ããã¡ãŒãžã«ã©ãã ãåã蟌ãŸãããã調ã¹ãŸãããMann-hrsACE2ã«ãFITCãâ»11ãšããèå è²çŽ ã§ç®å°ãã€ãããã¯ããã¡ãŒãžãšæ··ãåãããŸããããã®åŸããèå é¡åŸ®é¡ãâ»12ã§çŽæ¥èгå¯ããããããããŒãµã€ãã¡ããªãŒãâ»13ãšããè£ çœ®ã䜿ã£ãŠãåã ã®çްèãã©ããããèå ãçºããŠãããïŒïŒã©ããããMann-hrsACE2ãåã蟌ãã ãïŒãå®éçã«åæããŸããã
â»11 FITCïŒãã«ãªã¬ã»ã€ã³ã€ãœããªã·ã¢ããŒãïŒïŒç·è²ã®èå
ãçºããè²çŽ ã§ãã¿ã³ãã¯è³ªãæäœãªã©ã«çµåãããŠããã®æåšãç®èŠãæ©åšã§æ€åºããããã«çšããããã
â»12 èå
é¡åŸ®é¡ïŒèå
ãçºããç©è³ªã芳å¯ããããã®é¡åŸ®é¡ã现èå
ã®ç¹å®ã®ååãæ§é ãå¯èŠåããã®ã«åœ¹ç«ã€ã
â»13 ãããŒãµã€ãã¡ããªãŒïŒæ¶²äœäžã«æµ®éãã现èäžã€äžã€ã«ã¬ãŒã¶ãŒå
ãåœãŠã现èã®å€§ãããå
éšæ§é ã衚é¢ã«çµåããèå
ç©è³ªã®æç¡ãéãªã©ãé«éã§åæããè£
眮ã
ð¡ é©ãã®çºèŠïŒç ç©¶ã®äž»ãªãã€ã³ã
ç ç©¶ã®çµæãMann-hrsACE2ãæåŸ éãã®ç¹æ§ãæã¡ããã¯ããã¡ãŒãžã«å¹çããåã蟌ãŸããããšãæããã«ãªããŸããã
Mann-hrsACE2ã®ç¹æ§ãšãã¯ããã¡ãŒãžãžã®åã蟌ã¿
ãŸãã粟補ãããMann-hrsACE2ãSDS-PAGEãšãŠã§ã¹ã¿ã³ããããã§åæãããšãããéåžžã®hrsACE2ãããååéã倧ãããªã£ãŠããããšã確èªãããŸãããããã¯ãMann-hrsACE2ã«ãã³ããŒã¹ãªã©ã®ç³éãæ£ããä»å ãããŠããããšïŒãç³éä»å ãâ»14ïŒã匷ã瀺åããŠããŸãããã®ç³éä»å ããããå ç«çްèãžã®åã蟌ã¿ãä¿é²ããéµãšãªããŸãã
次ã«ããã¯ããã¡ãŒãžã«ããMann-hrsACE2ã®åã蟌ã¿ããããŒãµã€ãã¡ããªãŒã§è©äŸ¡ãããšãããMann-hrsACE2ã®æ¿åºŠãé«ããªãã«ã€ããŠããã¯ããã¡ãŒãžãžã®åã蟌ã¿å¹çãåçã«åäžããããšã瀺ãããŸããã以äžã®è¡šã«ãã®çµæã瀺ããŸãã
| Mann-hrsACE2æ¿åºŠ | ãã¯ããã¡ãŒãžã«ããåã蟌ã¿ç |
|---|---|
| 1 nM | 3% |
| 10 nM | 28% |
| 51 nM | 98% |
ãã®çµæã¯ãããã51 nMïŒããã¢ã«ïŒãšããæ¯èŒçäœãæ¿åºŠã§ãã»ãŒå šãŠã®ïŒ98%ïŒãã¯ããã¡ãŒãžãMann-hrsACE2ãåã蟌ãã ããšãæå³ããŸããããã¯ããã³ããŒã¹ãä»å ããããšã§ããã¯ããã¡ãŒãžãæã€ãã³ããŒã¹å容äœâ»15ãä»ããŠãMann-hrsACE2ãéåžžã«å¹çãã现èå ã«åã蟌ãŸããããšãæç¢ºã«ç€ºããŠããŸãã
â»14 ç³éä»å ïŒã°ãªã³ã·ã«åïŒïŒã¿ã³ãã¯è³ªã«ç³éãçµåããçäœå
ã®ä¿®é£Ÿåå¿ãã¿ã³ãã¯è³ªã®æ©èœãå®å®æ§ã现èéã®èªèãªã©ãæ§ã
ãªçç©åŠç圹å²ãæããã
â»15 ãã³ããŒã¹å容äœïŒãã¯ããã¡ãŒãžãæš¹ç¶çްèãªã©ã®å
ç«çްèã®è¡šé¢ã«ååšããå容äœã§ããã³ããŒã¹ãå«ãç³éãèªèããç
åäœãç°ç©ã®åã蟌ã¿ã仲ä»ããã
ð€ ãã®ç ç©¶ãæå³ããããšïŒæ·±ãèå¯
ãã®ç ç©¶ã®ææã¯ãæ°åã³ãããŠã€ã«ã¹å¯Ÿçã«ãããŠéåžžã«éèŠãªæå³ãæã£ãŠããŸãã
Mann-hrsACE2ã¯ãåã«æ°åã³ãããŠã€ã«ã¹ã现èã«äŸµå ¥ããã®ããããã¯ãããããšãããšããŠæ©èœããã ãã§ã¯ãããŸããããã³ããŒã¹ãšãããç®å°ããä»ããŠãã¯ããã¡ãŒãžã«å¹çããåã蟌ãŸããããšã§ããŠã€ã«ã¹ãããã¯ããã¡ãŒãžãšããå ç«çްèã®æšçããšããŠèªå°ããããšããäºéã®åœ¹å²ãæããå¯èœæ§ãç§ããŠããŸãã
å ·äœçã«ã¯ãMann-hrsACE2ãæ°åã³ãããŠã€ã«ã¹ã«çµåãããšããŠã€ã«ã¹ã¯Mann-hrsACE2ã®ãã³ããŒã¹ãä»ããŠãã¯ããã¡ãŒãžã«èªèããããããªããŸãããã¯ããã¡ãŒãžã¯ãŠã€ã«ã¹ãåã蟌ã¿ãæ¶åã»åè§£ããŸããããã«ããããŠã€ã«ã¹ã®ææåã奪ãã ãã§ãªãããã¯ããã¡ãŒãžããæåæç€ºçްèããšããŠæ©èœãããŠã€ã«ã¹ã®æçïŒæåïŒãä»ã®å ç«çްèïŒT现èãªã©ïŒã«æç€ºããããšã§ããã匷åã§æç¶çãªãçŽ°èæ§å ç«ãâ»16ãæŽ»æ§åãããå¯èœæ§ãèããããŸãã
ããã¯ãåŸæ¥ã®æäœæ²»çããã³ã€æŠç¥ã®éçãå æããèªç¶å ç«ãšç²åŸå ç«â»17ã®äž¡æ¹ãåºæ¿ããããšã§ãããåºç¯ãã€å¹æçãªæãŠã€ã«ã¹å¿çãåŒãåºãæ°ããã¢ãããŒããšãªããããããŸãããç¹ã«ããŠã€ã«ã¹ã®å€ç°ã«ãã£ãŠæ¢åã®ã¯ã¯ãã³ãæäœè¬ã®å¹æãäœäžããåé¡ã«å¯ŸããŠããå ç«çްèã«ããçŽæ¥çãªæé€ãä¿ããã®æ¹æ³ã¯ãæå¹ãªéžæè¢ãšãªãå¯èœæ§ãç§ããŠããŸãã
â»16 çŽ°èæ§å
ç«ïŒT现èãªã©ã®å
ç«çްèãçŽæ¥ãŠã€ã«ã¹ææçްèãæ»æããããä»ã®å
ç«çްèãæŽ»æ§åãããããããšã§ããŠã€ã«ã¹ãæé€ããå
ç«å¿çãé·æçãªé²åŸ¡ã«éèŠã
â»17 ç²åŸå
ç«ïŒé©å¿å
ç«ïŒïŒç
åäœã«äžåºŠææããããã¯ã¯ãã³ãæ¥çš®ãããããããšã§ç²åŸããããç¹å®ã®ç
åäœã«å¯Ÿããç¹ç°çãªå
ç«ãæäœç£çãçŽ°èæ§å
ç«ãªã©ãå«ãŸããã
ð ç§ãã¡ã®ç掻ã«ã©ã圹ç«ã€ïŒæªæ¥ãžã®æåŸ ãšã¢ããã€ã¹
ãã®ç ç©¶ã¯ãŸã åºç€æ®µéã§ãããå°æ¥çã«ç§ãã¡ã®ç掻ã«å€§ããªæ©æµãããããå¯èœæ§ããããŸãã
æ°ããæ²»çæ³ãäºé²æ³ãžã®å¯èœæ§
- ãã广çãªæãŠã€ã«ã¹è¬ã®éçºïŒ Mann-hrsACE2ã®ãããªã¿ã³ãã¯è³ªã¯ãæ°åã³ãããŠã€ã«ã¹ã®ææåæã«æäžããããšã§ããŠã€ã«ã¹ã®å¢æ®ãæããéçåãé²ãæ°ããæ²»çè¬ãšãªãå¯èœæ§ããããŸãã
- å€ç°æ ªãžã®å¯Ÿå¿ïŒ ãŠã€ã«ã¹ãå€ç°ããŠããACE2ãžã®çµåéšäœã¯æ¯èŒçä¿åãããããããããã®ã¢ãããŒãã¯å€ç°æ ªã«å¯ŸããŠã广ãçºæ®ããå¯èœæ§ããããŸãããŸããå ç«çްèã«ããæé€ãä¿ããããããå¹ åºãå€ç°æ ªã«å¯Ÿå¿ã§ããå¯èœæ§ããããŸãã
- äºé²çãªå¿çšïŒ å°æ¥çã«ã¯ãã¯ã¯ãã³ãšçµã¿åãããŠããã匷åãªå ç«é²åŸ¡ãèªå°ããããããã¯ãææãªã¹ã¯ã®é«ãç¶æ³ã§ã®äžæçãªäºé²çãšããŠå©çšã§ããå¯èœæ§ãèããããŸãã
æ¥åžžã§ã§ããå ç«åã¢ããã®ãã³ã
ãã®ãããªæå 端ã®ç ç©¶ãé²ãäžæ¹ã§ãç§ãã¡èªèº«ãæ¥ã ã®ç掻ã§å ç«åãé«ããææçã«åŒ·ãäœãäœãããšãéåžžã«éèŠã§ãã以äžã®ç¹ãå¿ãããŸãããã
- ãã©ã³ã¹ã®åããé£äºïŒ ãã¿ãã³ãããã©ã«ãã¿ã³ãã¯è³ªãè±å¯ã«å«ãé£äºãå¿ãããè žå ç°å¢ãæŽããçºé µé£åãªã©ãç©æ¥µçã«åãå ¥ããŸãããã
- ååãªç¡ç ïŒ ç¡ç äžè¶³ã¯å ç«æ©èœãäœäžãããŸãã質ã®è¯ãç¡ç ã7ïœ8æé確ä¿ããŸãããã
- é©åºŠãªéåïŒ ãŠã©ãŒãã³ã°ã軜ããžã§ã®ã³ã°ãªã©ãç¡çã®ãªãç¯å²ã§äœãåããããšã§ãè¡è¡ãä¿é²ãããå ç«çްèã®åããæŽ»çºã«ãªããŸãã
- ã¹ãã¬ã¹ç®¡çïŒ ã¹ãã¬ã¹ã¯å ç«æ©èœã«æªåœ±é¿ãåãŒããŸããè¶£å³ã®æéãæã€ããªã©ãã¯ã¹ã§ããç°å¢ãäœããªã©ãã¹ãã¬ã¹ãäžæã«è§£æ¶ããŸãããã
- åºæ¬çãªææå¯Ÿçã®ç¶ç¶ïŒ ææŽãããã¹ã¯ççšãææ°ã人混ã¿ãé¿ãããªã©ãåºæ¬çãªææå¯Ÿçã¯åŒãç¶ãéèŠã§ãã
ð§ ç ç©¶ã®éçãšä»åŸã®èª²é¡
ä»åã®ç ç©¶ã¯éåžžã«ææãªçµæã瀺ããŸãããããŸã åºç€ç ç©¶ã®æ®µéã§ãããå®çšåã«ã¯ããã€ãã®èª²é¡ããããŸãã
- in vitroïŒè©Šéšç®¡å ïŒç ç©¶ïŒ ä»åã®å®éšã¯äž»ã«è©Šéšç®¡å ã§è¡ãããŸãããå®éã®çäœå ïŒin vivoïŒã§ãMann-hrsACE2ãã©ãã ã广çã«æ©èœããå®å šã§ãããã確èªããããã«ã¯ãåç©å®éšãããã§ã®èšåºè©Šéšãå¿ èŠã§ãã
- å®å šæ§ãšå¯äœçšïŒ æ°ããã¿ã³ãã¯è³ªãäœå ã«æäžããéã«ã¯ãã¢ã¬ã«ã®ãŒåå¿ãäºæãã¬å¯äœçšããªãããå³å¯ãªå®å šæ§ã®è©äŸ¡ãäžå¯æ¬ ã§ãã
- 倧éçç£ãšã³ã¹ãïŒ æ²»çè¬ãšããŠå®çšåããããã«ã¯ãé«å質ãªMann-hrsACE2ãå®å®ããŠå€§éçç£ããæè¡ã®ç¢ºç«ãšãã³ã¹ãã®åæžã課é¡ãšãªããŸãã
- æäžæ¹æ³ïŒ ã©ã®ãããªæ¹æ³ã§äœå ã«æäžããã°æã广çãïŒæ³šå°ãåžå ¥ãªã©ïŒãæé©ãªæäžçµè·¯ãçšéã®æ€èšãå¿ èŠã§ãã
ãŸãšã
ä»åã®ç ç©¶ã¯ãæ°åã³ãããŠã€ã«ã¹ãå ç«çްèã«èªå°ããå¹ççã«æé€ããæ°ããã¿ã³ãã¯è³ªãMann-hrsACE2ãã®äœè£œã«æåãããšãããéåžžã«ç»æçãªææã§ãããã®ã¿ã³ãã¯è³ªã¯ããŠã€ã«ã¹ã®äŸµå ¥ããããã¯ããã ãã§ãªãããã¯ããã¡ãŒãžãšãã匷åãªå ç«çްèã«ãŠã€ã«ã¹ããé£ã¹ããããããšã§ãå ç«ã·ã¹ãã å šäœã®æŽ»æ§åãä¿ãå¯èœæ§ãç§ããŠããŸãã
ãŸã åºç€ç ç©¶ã®æ®µéã§ã¯ãããŸããããã®ã¢ãããŒããå°æ¥çã«ããã广çãªæ°åã³ãããŠã€ã«ã¹ææçã®æ²»çè¬ãäºé²æ³ãããã«ã¯ä»ã®ãŠã€ã«ã¹ææçã«å¯Ÿããæ°ããªæŠç¥ãžãšç¹ããããšã匷ãæåŸ ãããŸããä»åŸã®ãããªãç ç©¶ã®é²å±ã«æ³šç®ããŠãããŸãããã
é¢é£ãªã³ã¯é
- åœç«ææçç ç©¶æ
- åçåŽåç
- æ¥æ¬ãŠã€ã«ã¹åŠäŒ
- PubMed (çç©å»åŠæç®ããŒã¿ããŒã¹)
- Centers for Disease Control and Prevention (CDC) – Coronavirus Disease 2019 (COVID-19)
æžèªæ å ±
| DOI | pii: 90. doi: 10.1007/s10529-026-03755-z |
|---|---|
| PMID | 42473006 |
| PubMed URL | https://pubmed.ncbi.nlm.nih.gov/42473006/ |
| çºè¡å¹Ž | 2026 |
| èè å | Emami Hanie-Sadat, Vakili Bahareh, Esmaeil Nafiseh, Aucoin Marc G, Jahanian-Najafabadi Ali |
| èè æå± | Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.; Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.; Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.; Department of Chemical Engineering, Faculty of Engineering, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada.; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. jahanian@pharm.mui.ac.ir. |
| éèªå | Biotechnol Lett |